MedTrace Logo

Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C

NCT02528461 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 71

Last updated 2020-04-07

No results posted yet for this study

Summary

The purpose of the study is to investigate how the liver is affected with regard to inflammation and fibrosis during Sofosbuvir based treatment regimes of chronic hepatitis C.

In order to examine how the liver heals, we want to use blood samples to check for the occurrence of special liver inflammation cells (CD163 and CD206). To assess to which extent fibrosis disappear during treatment, we want to examine the liver with FibroScan (a type of ultrasound examination) and also preferably with extraction of a small tissue sample. We want to examine how the liver function as inflammation and scar tissue decrease, especially concerning the liver's ability to produce proteins. Furthermore, we want to examine with a gastroscopy, if the circulation of blood in the liver is improved after successful treatment with the expected result that potential varicose veins in the esophagus vanish.

Conditions

  • Hepatitis C

Interventions

DRUG

Galactose

A test to investigate the liver's ability to metabolize galactose to glucose by injecting galactose followed by measurements of blood glucose and the quantification of galactose in the urine.

PROCEDURE

Gastroscopy

PROCEDURE

Liver biopsy

PROCEDURE

Fibroscan

PROCEDURE

Liver vein catheterization

DRUG

Sofosbuvir

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Henning Grønbæk, Professor · Aarhus University Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2019-01-31
Completion
2020-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02528461 on ClinicalTrials.gov